Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.
2.

Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment.

Oikonomou E, Anastasiou Μ, Siasos G, Androulakis E, Psyrri A, Toutouzas K, Tousoulis D.

Curr Pharm Des. 2019 Jan 10. doi: 10.2174/1381612825666190111101459. [Epub ahead of print]

PMID:
30636595
3.

Chromosomal instability in oral squamous cell carcinoma.

S Papanikolaou V, Kyrodimos E, Tsiambas E, Giotakis E, Psyrri A, Ragos V, Chrysovergis A.

J BUON. 2018 Nov-Dec;23(6):1580-1582.

PMID:
30610780
4.

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.

Koutras A, Lazaridis G, Koliou GA, Kouvatseas G, Christodoulou C, Pectasides D, Kotoula V, Batistatou A, Bobos M, Tsolaki E, Papadopoulou K, Pentheroudakis G, Papakostas P, Pervana S, Petraki K, Chrisafi S, Razis E, Psyrri A, Bafaloukos D, Kalogeras KT, Kalofonos HP, Fountzilas G.

PLoS One. 2018 Dec 6;13(12):e0207707. doi: 10.1371/journal.pone.0207707. eCollection 2018.

5.

Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer.

Fountzilas E, Kotoula V, Tikas I, Manousou K, Papadopoulou K, Poulios C, Karavasilis V, Efstratiou I, Pectasides D, Papaparaskeva K, Varthalitis I, Christodoulou C, Papatsibas G, Chrisafi S, Glantzounis GK, Psyrri A, Aravantinos G, Koliou GA, Koukoulis GK, Pentheroudakis GE, Fountzilas G.

Oncotarget. 2018 Nov 2;9(86):35623-35638. doi: 10.18632/oncotarget.26256. eCollection 2018 Nov 2.

6.

A five split-field three dimensional conformal technique versus an anterior-posterior on in postoperative radiotherapy for gastric carcinoma: a multicenter comparative study using quality of life measurements as well as clinical and dosimetric parameters.

Zygogianni A, Fotineas A, Platoni K, Patatoukas G, Dilvoi M, Antypas C, Armpilia C, Arkadopoulos N, Psyrri A, Koukourakis G, Kouvaris J, Liakouli Z, Kyrgias G, Kalogeridi MA, Tolia M, Trogkanis N, Kougioumtzopoulou A, Kypraiou E, Kelekis N, Kouloulias V.

J BUON. 2018 Jul-Aug;23(4):1020-1028.

PMID:
30358207
7.

Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma.

Spathas N, Economopoulou P, Cheila M, Kotsantis I, Fanouriakis A, Kassara D, Psyrri A.

Front Oncol. 2018 Sep 26;8:409. doi: 10.3389/fonc.2018.00409. eCollection 2018.

8.

Endometrial carcinoma with tibial bone metastasis: a case report and literature review.

Makris GM, Mene J, Battista MJ, Chrelias G, Sergentanis TN, Psyrri A, Chrelias C.

J Obstet Gynaecol. 2018 Nov;38(8):1039-1047. doi: 10.1080/01443615.2017.1420759. Epub 2018 Jun 8. No abstract available.

PMID:
29884070
9.

Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights.

Foukas PG, Tsiodras S, Economopoulou P, Spathis A, Mademli M, Leventakos K, Psyrri A, Karakitsos P, Panayiotides IG.

IDCases. 2018 Feb 8;11:101-103. doi: 10.1016/j.idcr.2018.01.013. eCollection 2018.

10.

Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature.

Tsavaris O, Economopoulou P, Kotsantis I, Reppas L, Avgerinou C, Spathas N, Prevezanou M, Psyrri A.

Front Oncol. 2018 Mar 1;8:45. doi: 10.3389/fonc.2018.00045. eCollection 2018.

11.

Incidence and survival of gliomatosis cerebri: a population-based cancer registration study.

Georgakis MK, Spinos D, Pourtsidis A, Psyrri A, Panourias IG, Sgouros S, Petridou ET.

J Neurooncol. 2018 Jun;138(2):341-349. doi: 10.1007/s11060-018-2802-z. Epub 2018 Feb 20.

PMID:
29464663
12.

Cancer gene-panel testing identifies two loss-of-function alleles in PALB2 and PTEN.

Avgerinou C, Fostira F, Economopoulou P, Psyrri A.

Clin Genet. 2018 Jun;93(6):1250-1251. doi: 10.1111/cge.13138. Epub 2018 Feb 11.

PMID:
29430632
13.

Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis.

Poulakaki N, Makris GM, Papanota AM, Marineli F, Marinelis A, Battista MJ, Boehm D, Psyrri A, Sergentanis TN.

Clin Breast Cancer. 2018 Apr;18(2):157-167.e6. doi: 10.1016/j.clbc.2017.12.007. Epub 2017 Dec 16.

PMID:
29325859
14.

ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment.

Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, Psyrri A, Georgoulias V, Lianidou E.

Clin Cancer Res. 2018 Mar 15;24(6):1500-1510. doi: 10.1158/1078-0432.CCR-17-1181. Epub 2017 Dec 28.

PMID:
29284708
15.

Medical management of gastric cancer: a 2017 update.

Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A.

Cancer Med. 2018 Jan;7(1):123-133. doi: 10.1002/cam4.1274. Epub 2017 Dec 13. Review.

16.

Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).

Economopoulou P, Kotsantis I, Kyrodimos E, Lianidou ES, Psyrri A.

Oral Oncol. 2017 Nov;74:83-89. doi: 10.1016/j.oraloncology.2017.09.012. Epub 2017 Oct 2. Review.

PMID:
29103757
17.

Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.

Fountzilas G, Psyrri A, Giannoulatou E, Tikas I, Manousou K, Rontogianni D, Ciuleanu E, Ciuleanu T, Resiga L, Zaramboukas T, Papadopoulou K, Bobos M, Chrisafi S, Tsolaki E, Markou K, Giotakis E, Koutras A, Psoma E, Kalogera-Fountzila A, Skondra M, Bamia C, Pectasides D, Kotoula V.

Int J Cancer. 2018 Jan 1;142(1):66-80. doi: 10.1002/ijc.31023. Epub 2017 Sep 30.

18.

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.

Economopoulou P, Kotsantis I, Psyrri A.

ESMO Open. 2017 Feb 13;1(6):e000122. doi: 10.1136/esmoopen-2016-000122. eCollection 2016. Review.

19.

Anti-angiogenetic agents against tumor types and cardiovascular risk.

Economopoulou P, Kotsantis I, Psyrri A.

Hellenic J Cardiol. 2017 May - Jun;58(3):220-222. doi: 10.1016/j.hjc.2017.08.005. Epub 2017 Aug 24. No abstract available.

20.

Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.

Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, Avgeris M, Mazel M, Perisanidis C, Sasaki C, Alix-Panabières C, Lianidou E, Psyrri A.

Ann Oncol. 2017 Aug 1;28(8):1923-1933. doi: 10.1093/annonc/mdx206.

PMID:
28838214
21.

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.

Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenár É, Degardin M, Pateras IS, Langendijk JA, van Herpen CML, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB.

Ann Oncol. 2017 Sep 1;28(9):2213-2218. doi: 10.1093/annonc/mdx320.

PMID:
28651338
22.

p16, HPV, and Cetuximab: What Is the Evidence?

Bonner JA, Mesia R, Giralt J, Psyrri A, Keilholz U, Rosenthal DI, Beier F, Schulten J, Vermorken JB.

Oncologist. 2017 Jul;22(7):811-822. doi: 10.1634/theoncologist.2016-0433. Epub 2017 May 18. Review.

23.

Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.

Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Koutras A, Lazaridis G, Christodoulou C, Pentheroudakis G, Economopoulou P, Laskarakis A, Arapantoni-Dadioti P, Batistatou A, Sotiropoulou M, Aravantinos G, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G.

J Transl Med. 2017 Feb 13;15(1):30. doi: 10.1186/s12967-017-1134-7.

24.

A Retrospective Analysis of Toxicity and Efficacy for 2 Hypofractionated Irradiation Schedules Versus a Conventional One for Post-Mastectomy Adjuvant Radiotherapy in Breast Cancer.

Kouloulias V, Mosa E, Zygogianni A, Kypraiou E, Georgakopoulos J, Platoni K, Antypas C, Kyrgias G, Tolia M, Papadimitriou C, Psyrri A, Patatoukas G, Dilvoi M, Armpilia C, Theodorou K, Kalogeridi MA, Beli I, Kouvaris J, Kelekis N.

Breast Care (Basel). 2016 Oct;11(5):328-332. Epub 2016 Sep 28.

25.

Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes.

Kotoula V, Lakis S, Vlachos IS, Giannoulatou E, Zagouri F, Alexopoulou Z, Gogas H, Pectasides D, Aravantinos G, Efstratiou I, Pentheroudakis G, Papadopoulou K, Chatzopoulos K, Papakostas P, Sotiropoulou M, Nicolaou I, Razis E, Psyrri A, Kosmidis P, Papadimitriou C, Fountzilas G.

PLoS One. 2016 Sep 29;11(9):e0163138. doi: 10.1371/journal.pone.0163138. eCollection 2016.

26.

Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma.

Psyrri A, Rampias T, Burtness B.

JAMA Oncol. 2017 Jan 1;3(1):125. doi: 10.1001/jamaoncol.2016.3409. No abstract available.

PMID:
27607105
27.

The promise of immunotherapy in head and neck squamous cell carcinoma.

Economopoulou P, Agelaki S, Perisanidis C, Giotakis EI, Psyrri A.

Ann Oncol. 2016 Sep;27(9):1675-85. doi: 10.1093/annonc/mdw226. Epub 2016 Jul 5. Review.

PMID:
27380958
28.

Prognostic Impact of Pretreatment Plasma Fibrinogen in Patients with Locally Advanced Oral and Oropharyngeal Cancer.

Holzinger D, Danilovic I, Seemann R, Kornek G, Engelmann J, Pillerstorff R, Holawe S, Psyrri A, Erovic BM, Farwell G, Perisanidis C.

PLoS One. 2016 Jun 30;11(6):e0158697. doi: 10.1371/journal.pone.0158697. eCollection 2016.

29.

Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.

Economopoulou P, Kotsantis I, Psyrri A.

Curr Treat Options Oncol. 2016 Aug;17(8):40. doi: 10.1007/s11864-016-0419-z. Review.

PMID:
27315066
30.

The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A.

Ann Transl Med. 2016 May;4(9):173. doi: 10.21037/atm.2016.03.34. Review.

31.

Organ-specific gene modulation: Principles and applications in cancer research.

Economopoulou P, Psyrri A.

Cancer Lett. 2017 Feb 28;387:18-24. doi: 10.1016/j.canlet.2016.05.015. Epub 2016 May 17. Review.

PMID:
27224891
32.

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.

Gogas H, Kotoula V, Alexopoulou Z, Christodoulou C, Kostopoulos I, Bobos M, Raptou G, Charalambous E, Tsolaki E, Xanthakis I, Pentheroudakis G, Koutras A, Bafaloukos D, Papakostas P, Aravantinos G, Psyrri A, Petraki K, Kalogeras KT, Pectasides D, Fountzilas G.

J Transl Med. 2016 May 17;14(1):136. doi: 10.1186/s12967-016-0883-z.

33.

HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study.

Makatsoris T, Tsamandas AC, Strimpakos A, Alexopoulou Z, Dionysopoulos D, Pervana S, Konstantara A, Papakostas P, Samantas E, Rallis G, Dimou A, Pentheroudakis G, Papaparaskeva K, Psyrri A, Kalogeras KT, Syrigos K, Scopa CD, Fountzilas G.

Anticancer Res. 2016 Apr;36(4):1581-90.

PMID:
27069134
34.

Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: A systematic review and meta-analysis.

Perisanidis C, Psyrri A, Cohen EE, Engelmann J, Heinze G, Perisanidis B, Stift A, Filipits M, Kornek G, Nkenke E.

Cancer Treat Rev. 2015 Dec;41(10):960-70. Review.

PMID:
26604093
35.

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.

Kotoula V, Chatzopoulos K, Lakis S, Alexopoulou Z, Timotheadou E, Zagouri F, Pentheroudakis G, Gogas H, Galani E, Efstratiou I, Zaramboukas T, Koutras A, Aravantinos G, Samantas E, Psyrri A, Kourea H, Bobos M, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G.

Oncotarget. 2016 Jan 26;7(4):5074-87. doi: 10.18632/oncotarget.6231.

36.

Anticancer treatment and fertility: Effect of therapeutic modalities on reproductive system and functions.

Vassilakopoulou M, Boostandoost E, Papaxoinis G, de La Motte Rouge T, Khayat D, Psyrri A.

Crit Rev Oncol Hematol. 2016 Jan;97:328-34. doi: 10.1016/j.critrevonc.2015.08.002. Epub 2015 Aug 8. Review.

PMID:
26481950
37.

Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.

Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A.

Clin Cancer Res. 2016 Feb 1;22(3):704-13. doi: 10.1158/1078-0432.CCR-15-1543. Epub 2015 Sep 25.

38.

Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015.

Economopoulou P, Bourhis J, Psyrri A.

Am Soc Clin Oncol Educ Book. 2015:e323-8. doi: 10.14694/EdBook_AM.2015.35.e323. Review.

39.

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL.

J Natl Cancer Inst. 2015 May 19;107(8). pii: djv136. doi: 10.1093/jnci/djv136. Print 2015 Aug.

40.

Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC.

Strimpakos AS, Banerji U, Thavasu P, Tsilimagou A, Psyrri A, Syrigos KN.

Oncology. 2015;89(1):53-9. doi: 10.1159/000371711. Epub 2015 Feb 28.

PMID:
25766505
41.

Reply to D. Adkins et al.

Psyrri A, Economopoulou P, Dafni U.

J Clin Oncol. 2015 Apr 1;33(10):1225-6. doi: 10.1200/JCO.2014.59.9449. Epub 2015 Feb 23. No abstract available.

PMID:
25713435
42.

Androgen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone Treatment.

Vagia E, Economopoulou P, Oikonomopoulos N, Athanasiadis I, Dimitriadis G, Psyrri A.

Front Oncol. 2015 Feb 2;5:10. doi: 10.3389/fonc.2015.00010. eCollection 2015.

43.

Targeting angiogenesis in head and neck cancer.

Vassilakopoulou M, Psyrri A, Argiris A.

Oral Oncol. 2015 May;51(5):409-15. doi: 10.1016/j.oraloncology.2015.01.006. Epub 2015 Feb 10. Review.

PMID:
25680863
44.

Is there any potential clinical impact of serum phosphorus and magnesium in patients with lung cancer at first diagnosis? A multi-institutional study.

Kouloulias V, Tolia M, Tsoukalas N, Papaloucas C, Pistevou-Gombaki K, Zygogianni A, Mystakidou K, Kouvaris J, Papaloucas M, Psyrri A, Kyrgias G, Gennimata V, Leventakos K, Panayiotides I, Liakouli Z, Kelekis N, Papaloucas A.

Asian Pac J Cancer Prev. 2015;16(1):77-81.

45.

Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer.

Russmueller G, Moser D, Würger T, Wrba F, Christopoulos P, Kostakis G, Seemann R, Stadler V, Wimmer G, Kornek G, Psyrri A, Filipits M, Perisanidis C.

Oral Oncol. 2015 Mar;51(3):247-53. doi: 10.1016/j.oraloncology.2014.11.010. Epub 2014 Dec 17.

PMID:
25532817
46.

Beyond BRCA: new hereditary breast cancer susceptibility genes.

Economopoulou P, Dimitriadis G, Psyrri A.

Cancer Treat Rev. 2015 Jan;41(1):1-8. doi: 10.1016/j.ctrv.2014.10.008. Epub 2014 Nov 6. Review.

PMID:
25467110
47.

Adjuvant chemotherapy and acute toxicity in hypofractionated radiotherapy for early breast cancer.

Kouloulias V, Zygogianni A, Kypraiou E, Georgakopoulos J, Thrapsanioti Z, Beli I, Mosa E, Psyrri A, Antypas C, Armbilia C, Tolia M, Platoni K, Papadimitriou C, Arkadopoulos N, Gennatas C, Zografos G, Kyrgias G, Dilvoi M, Patatoucas G, Kelekis N, Kouvaris J.

World J Clin Cases. 2014 Nov 16;2(11):705-10. doi: 10.12998/wjcc.v2.i11.705.

48.

In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features.

Papadavid E, Korkolopoulou P, Levidou G, Saetta AA, Papadaki T, Siakantaris M, Nikolaou V, Oikonomidi A, Chatziandreou I, Marinos L, Kolialexi A, Stratigos A, Rigopoulos D, Psyrri A, Patsouris E, Antoniou C.

Exp Dermatol. 2014 Dec;23(12):931-3. doi: 10.1111/exd.12547.

PMID:
25267489
49.

Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).

Kotoula V, Bobos M, Vassilakopoulou M, Tsolaki E, Chrisafi S, Psyrri A, Lazaridis G, Papadopoulou K, Efstratiou I, Michail-Strantzia C, Debelenko LV, Kosmidis P, Fountzilas G.

Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):60-70. doi: 10.1097/PAI.0000000000000028.

PMID:
25153496
50.

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA.

Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12.

Supplemental Content

Loading ...
Support Center